Biotechnology company Biogen, Inc. (BIIB) reported Wednesday that net income attributable to the company for the fourth quarter grew to $266.8 million or $1.83 per share from $249.7 million or $1.71 per share in the prior-year quarter.
Excluding items, adjusted earnings for the quarter were $3.44 per share, compared to $2.95 per share in the year-ago quarter.
On average, 26 analysts polled expected the company to report earnings of $3.36 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenue for the quarter grew 2.9 percent to $2.46 billion from $2.39 billion in the same quarter last year. Revenues were up 2.4 percent in constant currency. Analysts expected revenues of $2.42 billion for the quarter.
Looking ahead to fiscal 2025, the company now projects adjusted earnings in a range of $15.25 to $16.25 per share on a revenue decline in the mid-single digits at constant currency as further declines in multiple sclerosis product revenue are expected to be partially offset by increases in revenue from product launches..
The Street is looking for earnings of $16.24 per share on a revenue decline of 2.31 percent to $9.42 billion for the year.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.